Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sapiens ( (SPNS) ) has issued an update.
On October 19, 2025, Sapiens International Corporation N.V. announced the early redemption of its Series B Debentures, which are traded on the Tel Aviv Stock Exchange. The redemption, scheduled for November 10, 2025, will involve paying holders the outstanding principal and accrued interest, totaling approximately NIS 66.6 million (around US $20 million). This move will result in the delisting of the debentures from the TASE, fully discharging the company’s obligations to the debenture holders. Initially issued in 2017, the Series B Debentures were part of a shelf offering in Israel, bearing a fixed annual interest rate of 3.37% and were not offered in the United States.
The most recent analyst rating on (SPNS) stock is a Hold with a $47.00 price target. To see the full list of analyst forecasts on Sapiens stock, see the SPNS Stock Forecast page.
Spark’s Take on SPNS Stock
According to Spark, TipRanks’ AI Analyst, SPNS is a Neutral.
Sapiens’ strong financial performance is the primary driver of its stock score, supported by robust revenue growth and a well-managed balance sheet. The technical analysis indicates a bullish trend, though overbought conditions suggest caution. The high P/E ratio raises valuation concerns, partially offset by a modest dividend yield.
To see Spark’s full report on SPNS stock, click here.
More about Sapiens
Sapiens International Corporation N.V. operates in the software industry, focusing on providing software solutions for the insurance sector. The company specializes in offering products that enhance the efficiency and effectiveness of insurance operations, with a market focus primarily on the Israeli market.
Average Trading Volume: 1,020,023
Technical Sentiment Signal: Buy
Current Market Cap: $2.41B
For an in-depth examination of SPNS stock, go to TipRanks’ Overview page.